203 related articles for article (PubMed ID: 29718366)
21. Cystic glioblastoma: an evaluation of IDH1 status and prognosis.
Sarmiento JM; Nuño M; Ortega A; Mukherjee D; Fan X; Black KL; Patil CG
Neurosurgery; 2014 Jan; 74(1):71-5: discussion 75-6. PubMed ID: 24089051
[TBL] [Abstract][Full Text] [Related]
22. Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment.
Stadlbauer A; Roessler K; Zimmermann M; Buchfelder M; Kleindienst A; Doerfler A; Heinz G; Oberndorfer S
Mol Imaging Biol; 2019 Aug; 21(4):747-757. PubMed ID: 30361791
[TBL] [Abstract][Full Text] [Related]
23. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
Gerstner ER; Zhang Z; Fink JR; Muzi M; Hanna L; Greco E; Prah M; Schmainda KM; Mintz A; Kostakoglu L; Eikman EA; Ellingson BM; Ratai EM; Sorensen AG; Barboriak DP; Mankoff DA;
Clin Cancer Res; 2016 Oct; 22(20):5079-5086. PubMed ID: 27185374
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
25. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
[TBL] [Abstract][Full Text] [Related]
26. Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status.
Wee CW; Kim E; Kim N; Kim IA; Kim TM; Kim YJ; Park CK; Kim JW; Kim CY; Choi SH; Kim JH; Park SH; Choe G; Lee ST; Chang JH; Kim SH; Suh CO; Kim IH
Radiother Oncol; 2017 Apr; 123(1):106-111. PubMed ID: 28302331
[TBL] [Abstract][Full Text] [Related]
27. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
[TBL] [Abstract][Full Text] [Related]
28. Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival.
Lasocki A; Gaillard F; Tacey M; Drummond K; Stuckey S
J Clin Neurosci; 2018 Jan; 47():168-173. PubMed ID: 28988652
[TBL] [Abstract][Full Text] [Related]
29. High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.
Puig J; Blasco G; Daunis-I-Estadella J; Alberich-Bayarri A; Essig M; Jain R; Remollo S; Hernández D; Puigdemont M; Sánchez-González J; Mateu G; Wintermark M; Pedraza S
Neuroradiology; 2016 Jan; 58(1):17-26. PubMed ID: 26438560
[TBL] [Abstract][Full Text] [Related]
30. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features of small cell glioblastomas.
Takeuchi H; Kitai R; Hosoda T; Yamada S; Hashimoto N; Kikuta K; Shimizu Y; Kimura H
J Neurooncol; 2016 Apr; 127(2):337-44. PubMed ID: 26725094
[TBL] [Abstract][Full Text] [Related]
32. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
33. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
[TBL] [Abstract][Full Text] [Related]
34. Metabolic Tumor Microenvironment Characterization of Contrast Enhancing Brain Tumors Using Physiologic MRI.
Stadlbauer A; Marhold F; Oberndorfer S; Heinz G; Zimmermann M; Buchfelder M; Heynold E; Kinfe TM
Metabolites; 2021 Sep; 11(10):. PubMed ID: 34677383
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
36. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
[TBL] [Abstract][Full Text] [Related]
37. The angiogenic switch leads to a metabolic shift in human glioblastoma.
Talasila KM; Røsland GV; Hagland HR; Eskilsson E; Flønes IH; Fritah S; Azuaje F; Atai N; Harter PN; Mittelbronn M; Andersen M; Joseph JV; Hossain JA; Vallar L; Noorden CJ; Niclou SP; Thorsen F; Tronstad KJ; Tzoulis C; Bjerkvig R; Miletic H
Neuro Oncol; 2017 Mar; 19(3):383-393. PubMed ID: 27591677
[TBL] [Abstract][Full Text] [Related]
38. Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations.
McCormack RM; Zhu P; Dono A; Takayasu T; Bhatia A; Blanco AI; Tandon N; Ostrom QT; Gonzales A; Moreno S; Ballester LY; Esquenazi Y
World Neurosurg; 2021 May; 149():e894-e912. PubMed ID: 33516867
[TBL] [Abstract][Full Text] [Related]
39. Novel insights into vascularization patterns and angiogenic factors in glioblastoma subclasses.
Conroy S; Wagemakers M; Walenkamp AM; Kruyt FA; den Dunnen WF
J Neurooncol; 2017 Jan; 131(1):11-20. PubMed ID: 27633774
[TBL] [Abstract][Full Text] [Related]
40. Correlation Between Tumor Location and Clinical Properties of Glioblastomas in Frontal and Temporal Lobes.
Li HY; Sun CR; He M; Yin LC; Du HG; Zhang JM
World Neurosurg; 2018 Apr; 112():e407-e414. PubMed ID: 29355809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
